These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12422001)

  • 41. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study].
    Bunchuk NV; Rumiantseva OA; Loginova EIu; Bochkova AG; Storozhakov GI; Ettinger OA; Kosiura SD; Kamalova RG; Valishina LM
    Ter Arkh; 2010; 82(10):41-6. PubMed ID: 21341463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
    Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
    J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment.
    Breban M; Ravaud P; Claudepierre P; Baron G; Henry YD; Hudry C; Euller-Ziegler L; Pham T; Solau-Gervais E; Chary-Valckenaere I; Marcelli C; Perdriger A; Le Loët X; Wendling D; Fautrel B; Fournié B; Combe B; Gaudin P; Jousse S; Mariette X; Baleydier A; Trape G; Dougados M;
    Arthritis Rheum; 2008 Jan; 58(1):88-97. PubMed ID: 18163509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
    Braun J; Davis J; Dougados M; Sieper J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2006 Mar; 65(3):316-20. PubMed ID: 16096329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
    Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
    Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis.
    Matsuda J; Kaburaki T; Kobayashi S; Numaga J
    Jpn J Ophthalmol; 2013 Jan; 57(1):104-7. PubMed ID: 23108527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
    Saeed A; Khan M; Elmamoun M; Brady M; Morrissey S; Fraser AD
    Rheumatol Int; 2012 May; 32(5):1305-9. PubMed ID: 21286722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.
    Ternant D; Mulleman D; Lauféron F; Vignault C; Ducourau E; Wendling D; Goupille P; Paintaud G
    Br J Clin Pharmacol; 2012 Jan; 73(1):55-65. PubMed ID: 21692827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
    Stone M; Salonen D; Lax M; Payne U; Lapp V; Inman R
    J Rheumatol; 2001 Jul; 28(7):1605-14. PubMed ID: 11469469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of Life and Clinical Response to On-Demand Maintenance Doses of Infliximab in Patients With Ankylosing Spondylitis.
    Sengupta S; Ray J; Ghosh B
    J Clin Rheumatol; 2015 Oct; 21(7):355-8. PubMed ID: 26398462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.